EU Clinical Trial Regulation 536/2014 - Compliance, Implementation and Best Practices Training
| Available : All Days | Presented By : John E. Lincoln |
| Category : Pharmaceutical | Event Type : Recorded Webinar |
For group or any booking support, contact: cs@educationsgrow.com + 1 (844) 240-7679 (US Toll Free)
This EU Clinical Trial Regulation (EU CTR) 536/2014 training provides a comprehensive understanding of the requirements for conducting clinical studies across the European Union, covering both drugs and biologics. Participants will gain up-to-date knowledge of EU-GCP standards aligned with the new regulatory framework and learn about the EU Pharmacovigilance Directive as it relates to safety reporting, inspections, and collaboration with European regulators.
The course highlights the key changes introduced by the EU Clinical Trial Regulation, impacting all new and ongoing trials across EU Member States. It also explains licensing procedures for drugs, biologics, and combination products, including how to obtain Marketing Authorizations through national, mutual recognition, decentralized, and centralized procedures within the EU and EEA.
Attendees will explore the structure and functions of EU regulatory agencies, understand the application and review processes under each pathway, and gain practical insights into managing submissions efficiently. This program is ideal for professionals seeking to navigate EU CTR 536/2014 compliance, optimize CTIS submissions, and stay ahead of evolving clinical trial and pharmacovigilance regulations.
Learning Objectives:-
By the end of this EU Clinical Trial Regulation (EU CTR) 536/2014 Compliance & Implementation Training, attendees will gain a clear and practical understanding of the current EU regulatory requirements governing clinical trials, drug development, and product registration across Member States.
This updated course provides participants with competitive insights into critical topics such as:
Agenda:-
Session 1: EU’s New Regulation 535/2014 on Clinical Trials, 2022 (77 slides)
Break
Session 2: ICH Q7, API CGMPs and QMS (81 slides)
Break
Session 3: Risk Management in EU New Drug Development (53 slides)
Session 4: Investigational Medicinal Products (IMPs) (22 slides)
Session 5: EU Clinical Trials Application Process (36 slides)
Review
Q & A
Who Will Benefit?
John E. Lincoln is the Principal of J. E. Lincoln and Associates LLC, a consulting company, with over 32 years of experience in U.S. FDA-regulated industries, 18 of which as a full-time independent FDA-regulated industry consultant. Mr. Lincoln has worked with companies from start-up to Fortune 100, in the U.S., Mexico, Canada, France, Germany, Sweden, China, and Taiwan. He specializes in quality assurance, regulatory affairs, QMS / CGMP audits, problem remediation and FDA responses, new/changed product 510(k)s, process/product/equipment including QMS and software validations, ISO 14971 product risk management files/reports, Design Control / Design History Files, Technical Files. He’s held positions in Manufacturing Engineering, QA, QAE, and Regulatory Affairs, to the level of Director and VP (R&D).